Advocacy intelligence hub — real-time data for patient organizations
FINANCIAL LANDSCAPE SUMMARY
Total programs
XARELTO
(RIVAROXABAN)standardJanssen Pharmaceuticals, Inc.
Factor Xa Inhibitor [EPC]
12.1 Mechanism of Action XARELTO is a selective inhibitor of FXa. It does not require a cofactor (such as Anti-thrombin III) for activity. Rivaroxaban...
Kris Ann P Schultz
Children's Oncology Group
James I Geller
Children's Oncology Group
📍 Birmingham, Alabama
Kris Ann P Schultz, MD
Children's Minnesota
Dana A. Hill, MD
Children's National Research Institute
Douglas R Stewart, M.D.
National Cancer Institute (NCI)
📍 Bethesda, Maryland
Isabelle Ruchonnet-Métrailler, MD PhD
University Hospital, Geneva